| Ticker Details |
|
Taysha Gene Therapies, Inc.
|
| IPO Date: |
September 24, 2020 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$1.58B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.27 | 4.11%
|
| Avg Daily Range (30 D): |
$0.22 | 3.88%
|
| Avg Daily Range (90 D): |
$0.16 | 3.17%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.7M |
| Avg Daily Volume (30 D): |
2.22M |
| Avg Daily Volume (90 D): |
2.22M |
| Trade Size |
| Avg Trade Size (Sh.): |
200 |
| Avg Trade Size (Sh.) (30 D): |
109 |
| Avg Trade Size (Sh.) (90 D): |
123 |
| Institutional Trades |
| Total Institutional Trades: |
671 |
| Avg Institutional Trade: |
$1.91M |
| Avg Institutional Trade (30 D): |
$2.11M |
| Avg Institutional Trade (90 D): |
$1.84M |
| Avg Institutional Trade Volume: |
.52M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.37M |
| Avg Closing Trade (30 D): |
$2.58M |
| Avg Closing Trade (90 D): |
$2.11M |
| Avg Closing Volume: |
578.58K |
|
|
| Financials |
| |
TTM |
Q1 2026 |
Q4 2025 |
|
Basic EPS
|
$-.38
|
$-.12
|
$-.08
|
|
Diluted EPS
|
$-.38
|
$-.12
|
$-.08
|
|
Revenue
|
$7.47M
|
$M
|
$5.49M
|
|
Gross Profit
|
|
|
|
|
Net Income / Loss
|
$-129.88M
|
$-42.41M
|
$-27.85M
|
|
Operating Income / Loss
|
$-132.56M
|
$-43.49M
|
$-28.3M
|
|
Cost of Revenue
|
|
|
|
|
Net Cash Flow
|
$160.15M
|
$-43.19M
|
$22.59M
|
|
PE Ratio
|
|
|
|
|
|
|